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The Formulary Fix Buries Fritz & 
Harvey: Drug Promotion Escapes its 
Past Constraints 
James T. O’Reilly* 
I. Setting the Scene 
The young in-house lawyer, a recent W&L Law graduate, 
enters the meeting on the executive floor of corporate headquarters 
and observes the vigorous debate among the team of 
pharmaceutical marketing experts. One group wants to ask senior 
management to invest $7 million to conduct an additional clinical 
trial at three prestigious hospitals, in order to request that the 
FDA would allow the company to make the newly expanded claim 
that their ten-year-old acne drug “Alepsima” will cure hangnail.  
This is the correct “by the book” route1 to selling a greater 
volume of Alepsima, at a greater profit, beginning in an estimated 
twenty-six months following submission of test results to the Food 
and Drug Administration (FDA). They expect that a label change 
will be approved, after the FDA allows the hangnail claim 
following a detailed medical evaluation of the clinical trial results, 
and after the FDA’s team of reviewers of the company’s 
supplemental new drug application feel they have seen enough 
supporting data, so that their approval of this drug for hangnail 
will be unassailable.  
Another expert group of company marketers wants to push 
more Alepsima sales today, by overtly promoting its use against 
hangnails in trade-show booth presentations and sales visits to 
dermatologists and podiatrists, without awaiting FDA blessings. 
This group cites an in-house dermatology research team that 
conducted a less formal review of the technical literature, and 
found sixteen doctors whose hangnail patients had responded well 
                                                                                                     
 * Professor, University of Cincinnati College of Medicine. 
 1. 21 C.F.R. § 314.70 (2016). The supplemental new drug application must 
be accompanied by valid clinical data acceptable to FDA scientists. 
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to their use of Alepsima. The first group replies, “No! Such 
aggressive claims will get us into trouble.”  
At the head of the table, the division Vice-President turns to 
the young lawyer and says: “How much trouble will we be in, if we 
use the hangnail claim in sales presentations to sell Alepsima to 
doctors tomorrow?”  
Hundreds of miles away, the maker of Hangtough® ointment 
has its sales team wondering what defensive moves will be needed, 
in response to rumors that Alepsima might intrude upon 
Hangtough’s FDA-approved use as the best-selling brand for 
hangnails. Is litigating the right strategy? Will the FDA respond 
to our pleas, and defend us? How much is our lost market share 
potentially worth? 
And, a thousand miles away, the Regional Drug Compliance 
Director of the FDA is oblivious to both, bemoaning yet another 
budget cut from the Trump Administration, which reduces the 
FDA’s ability to monitor claims on drug labels for the latest 
gene-derived cancer drugs. If she had been asked she would 
probably respond: “Hangnail? Who cares? When we have death 
risks surrounding neonatal stem cell infusion, why spend the 
scarce resources we have on these less impactful decisions?” 
So, the conflicts of Lanham Act2 remedy, the long shot of FDA 
and Justice Department cooperation to halt misbranding, and the 
potential for jeopardizing an income stream of millions to win 
marginal additional sales in the thousands, makes the young 
lawyer hesitate. If she or he is as bright as Chris Hurley, there will 
be a brilliant answer. Charles Dickens would see me as the Ghost 
of Christmas Past, and Chris as the smiling angel of the 
pharmaceutical industry’s future. What the Dickens should come 
from this scenario today? 
                                                                                                     
 2. Trademark Act of 1946 (Lanham Act), Pub. L. No. 79-489, 60 Stat. 427 
(codified as amended at 15 U.S.C. §§ 1051–1127 (2012)). 
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II. Yesterday’s Blues 
Fritz Lanham of Texas3 and Harvey Wiley of Indiana4 never 
met, but their respective legacies in legislation have given the 
federal courts numerous challenges to decipher. Fritz intended to 
update the federal trademark laws in the boom years of postwar 
commerce after World War II; the less busy federal courts had the 
time and the intellectual power to help Fritz create the legal 
protection of the statutory rights of trademark owners.  
Harvey wanted to stop snake-oil salesmen who hawked their 
claimed curative potions with loud promises but an absence of 
supporting data and safety research.5 If Harvey and Fritz had met, 
chances are they would not have regarded the complexities of the 
2018-era presentation of drug benefit claims6 as a theme for new 
legislative attention. Their federal judges had the time and the 
docket capacity to make such intellectually fascinating decisions. 
Our district court judges today are swamped; just ask them when 
the vacant seats on their district court bench will be filled. So, a 
little statutory ambiguity about the additional benefit claims for a 
drug seems to be fine, since statutes tend to grow ambiguities as 
they age. 
Ambiguities in statutory coverage are as old as Hammurabi or 
at least the Magna Carta. The king’s interpretation of the royal 
charter controlled the outcome; the royal bench of jurists, like the 
Royal Assizes of olden times, could offer their interpretation, but 
the actual creator of that charter was always there to say what had 
been intended. So, the American Article III judges, begotten by our 
anti-royalist Constitution, should in theory enjoy the opportunity 
to bring Harvey and Fritz together, as the Food Drug & Cosmetic 
                                                                                                     
 3. Rep. Fritz Lanham represented the 12th Congressional District in Texas 
and sponsored the Lanham Act. Id. §§ 1051–1127. 
 4. State Chemist of Indiana, later Chief Chemist of the U.S. Department of 
Agriculture, and first Commissioner of Food & Drugs after adoption of the Pure 
Foods & Drugs Act. Federal Food and Drugs Act of 1906 (Wiley Act), Pub. L. No. 
59-384, 34 Stat. 768 (repealed 1938). 
 5. A useful biography is found on Wikipedia. Harvey Washington Wiley, 
WIKIPEDIA, https://en.wikipedia.org/wiki/Harvey_Washington_Wiley (last 
updated Oct. 31, 2017) (last visited Jan. 19, 2018) (on file with the Washington 
and Lee Law Review).  
 6. See 21st Century Cures Act, Pub. L. No. 114-255, § 3037, 130 Stat. 1033, 
1105 (2016) (codified as amended at 21 U.S.C. § 355 (2012)).  
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Act7 and the Lanham Act8 might be used to focus the legal 
community’s attention upon sales of hangnail drugs or other 
weightier problems.  
And so, on this same day as the stage is set for our dermatology 
drama, Mr. John Jones, suffering from painful hangnail, asks the 
advanced practice nurse in the local retail store “Minute Clinic” 
what she can give him for his annoying dermatological problem. 
“On aisle three we have Hangtough, but take this prescription to 
the counter and they’ll give you Alepsima, and it should be cured 
more quickly!” 
But first, we go back to visit our young lawyer in the drug 
company conference room. The Vice President’s question still 
hangs in the air: what trouble will we be in by promoting 
Alepsima? 
One of Virginia’s brightest young lawyers, after his W&L 
graduation in a few months, will be answering that question 
bravely in his excellent analysis of the interweaving of Lanham 
and Food Drug & Cosmetic Act remedies. Yet this tired and 
somewhat more experienced counselor with scars and battle stars 
from many past battles over forty-four years, would hesitate and 
will say: “It depends!” 
III. Warfare in the Pharma Trenches 
The commercial wars among pharmaceutical companies of 
today are different than in ancient times. In the old days, drug 
marketing lawyers would think “Lanham Act unfair competition” 
was occurring if our sales representative had found a competitor’s 
sales brochure making the unapproved new claims, typically inside 
a dermatologist’s waiting room. Trade shows, contract reps, detail 
reps and continuing medical education were the battlefields of old 
time prescription drug sales.9 Nuances of the Lanham Act 
resonated with courts and earned scholarly attention in esoteric 
                                                                                                     
 7. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 
(1938) (codified as amended at 21 U.S.C. § 321 et seq. (2012)). 
 8. Trademark Act of 1946 (Lanham Act), Pub. L. No. 79-489, 60 Stat. 427 
(codified as amended at 15 U.S.C. §§ 1051–1127 (2012)). 
 9. 2 JAMES T. O’REILLY & KATHARINE A. VAN TASSEL, FOOD & DRUG 
ADMINISTRATION ch. 15 (4th ed. 2017). 
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analyses. In the primary article of this issue, W&L’s Chris Hurley 
has spotted those issues very well. 
“Back in the day,” some tradition-bound drug companies 
fought the last war, not the new war, and that has made all of the 
difference. When the Supreme Court in Weinberger v. Hynson, 
Westcott & Dunning, Inc.10 allowed great deference to an FDA 
administrative remedy, withdrawal of the New Drug Application 
(NDA) as punishment for misconduct, the message sent by the 
FDA and the Court was echoed in company meetings with the FDA 
for years: beware losing your base product approval. If you dare to 
push the envelope of permissible claims, then the FDA would win 
in court, after Hynson, when the FDA undertakes the withdrawal 
of your prior FDA approval of your drug.  
Any old-school commentator is in danger of talking “inside 
baseball” as these nuances evolve, but their relevance will be 
apparent in retrospective. The Hurley Note’s analysis is very well 
stated. But, the FDA’s major years of achieving practical success 
with threats, came without the FDA having to bring much 
litigation to police the marketers’ efforts for expansion of product 
benefit claims. In poker terms, the FDA could just call for “Hynson 
deference,” and the drug industry player would fold its cards, the 
benefit would not be claimed, and no court would need to become 
involved.11 
Warriors for the totally compliant drug maker in the olden 
days might beg the FDA to act against the aggressive hustling of 
an unapproved claim for a competing drug. But, the agency would 
choose its targets very strategically, in order to scare many other 
firms into compliance with one visible victim. The FDA could use 
misbranding or an “unapproved new drug” violation as the 
charge,12 and would have a variety of ways to attack. On rare 
occasions, there would be a competing drug firm, behind the 
scenes, begging the FDA to initiate a blockbuster criminal 
prosecution that, when given publicity, would drive the stock price 
of the offending drug firm into the ditch. The drug promotion 
                                                                                                     
 10. 412 U.S. 609 (1973). 
 11. See generally James T. O’Reilly, Losing Deference in the FDA’s Second 
Century: Judicial Review, Politics, and a Diminished Legacy of Expertise, 93 
CORNELL L. REV. 939, 944 (2008). 
 12. 21 U.S.C. §§ 321, 333, 355 (2012). 
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conflict’s harsh bite was being threatened at a time when 
promotion of new uses for an approved drug was all about sales 
and the stock price of the pharmaceutical marketer. 
I plead guilty to having been a master practitioner of those 
black arts of stimulating enforcers to act against bad behavior. For 
reasons of legal ethics, I cannot reveal whose inbox received a 
letter bomb and who did a nationwide recall while paying a very 
large penalty. But, it felt terrific when a month later there came 
an unsolicited call from a headhunter legal search firm who 
described a regulatory law job in the home city of my wounded 
competitor. (I declined to interview after telling the recruiter “I 
made that opening, I’m not going to fill it!”) 
That old-style war of off-label promotion is not yet over. On 
September 22, 2017, we heard the last of a long-running tragedy, 
the Novelion case.13 Novelion bought a tech company and inherited 
a hugely expensive cancer drug that had been approved only for 
certain rare cancer cases, one medical use that costs private payers 
or Medicare between $250,000 and $300,000 per rare cancer 
patient per year. I say “inherited” because the earlier drug firm 
that launched the drug, Aegerion, imploded. Its sales reps had 
been hustling the very expensive drug for as-yet-unapproved 
additional types of cancer. Their hustle to sell more to Medicare 
and Medicaid patients crossed the line, and three employees hired 
an attorney and filed a False Claims Act complaint (probably after 
being terminated).14  
The outcome of the Novelion case was perhaps the last battle 
using the old ways of war: criminal convictions for two counts of 
misbranding the drug; a tough federal oversight, the “deferred 
prosecution agreement” was accepted by Novelion; the firm paid 
$36 million in penalties to the Justice Department and $4.1 million 
to the Securities & Exchange Commission. Three former 
employees who quit and blew the whistle received $4.7 million as 
their share of the government’s recovery.  
                                                                                                     
 13. See generally United States v. Aegerion Pharm., Inc., No. 17-10288, 2017 
U.S. Dist. LEXIS 191677 (D. Mass. Nov. 20, 2017); see also Press Release, U.S. 
Dep’t Justice, Drug Maker Aegerion Agrees to Plead Guilty; Will Pay More Than 
$35 Million to Resolve Criminal Charges and Civil False Claims Allegations 
(Sept. 22, 2017) (on file with author).  
 14. See Press Release, U.S. Dep’t Justice, supra note 13.   
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I hope we have heard the last; Novelion made no press release, 
hopes it will slip quietly through the probationary “deferral” 
period, and hopes that it will not be further prosecuted. The drug 
remains on the highly specialized cancer market but is not being 
offered to doctors “off label” while the tight scrutiny period unfolds. 
IV. New Ways of War 
That was then, this is now. I speak in past tense terms because 
after December 16, 2016, the “off label” promotion moves from 
illegal in some doctor’s waiting room to legal in the boardroom of a 
health insurance conglomerate. Yes, a new law adopted on that 
day will allow the “Formulary Fix,” the targeted promotional 
efforts for those as-yet-unapproved medical uses, which now can 
legally be promoted. 
Promotion of the unapproved use is now permitted to be given 
to the set of most influential and powerful drug “payers” like 
insurance carriers and state Medicaid agencies, as an expanded 
set of benefit claims, for expanding the uses of an already-approved 
drug product. Called the 21st Century Cures Act,15 the new 
legislation is an important and subtle change to the 1962–2016 
way of operating the process for addition of new benefits for 
existing licensed drugs. When the new drug approval system was 
placed in operation under the 1962 statutory amendments, 
healthcare providers did not take their drug decision-making from 
large corporate payers like Aetna or Humana or Medicaid; today, 
the majority of drug prescribing is being done by employed rather 
than independent doctors.16 With employment comes the rules of 
the employer; with those rules comes the Formulary Fix. If the cost 
to treat this patient is being paid by an entity, it can impose its 
restraints on what it will purchase and what its employed 
physicians will prescribe. Hence, the patient gets what the 
provider sees in the Formulary as the designated drug of choice for 
the condition reported by the ailing patient.  
                                                                                                     
 15. Pub. L. No. 114-255, § 3037, 130 Stat. 1033, 1105 (2016). 
 16. See generally JAMES O’REILLY & MARY ELLEN KEEGAN, HEALTHCARE 
EMPLOYMENT GUIDE (BNA 2017). 
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Just as the World War I invention of the armored tank made 
horse cavalry obsolete, the Formulary Fix renders the Lanham and 
misbranding debates less likely to carry much weight in the future. 
The 21st Century Cures Act is subtle but strategic. A drug 
development company’s first stage approval of its base line drug 
wins approval of the new drug application.17 That company begins 
selling that drug for that medical indication. The company soon 
realizes its drug could also cure another ailment. At that point, the 
company then can choose: it could gather clinical data and ask 
FDA to expand the permitted label claims of drug benefit18—the 
focus of our drug marketing off-label discussion today. Or, the 
company now is able to take the additional medical uses for that 
product and present them, not to FDA gatekeepers, but to the 
intermediary companies called “pharmacy benefit managers,” the 
intermediate players who actually pay for the Medicaid drugs or 
who approve the prices that health insurer clients will pay when 
they purchase drugs.19 
Is the waiting time for FDA’s blessing upon one’s 
supplemental new drug application still needed? Times have 
changed; in ancient times, Ms. Jones once took a prescription for 
acne medication to the Smith Drug Store and paid real cash for the 
medication. Today, online promotion to doctors will cut Ms. Jones 
out of the decision process; electronic messages from the doctor to 
the insurance company will check if the drug that the doctor 
wishes to prescribe is “on the (provider’s) Formulary”. If it is, then 
the order is passed along electronically to a mail order pharmacy, 
and Ms. Jones gets her medicine in one to three days’ delivery. 
The Formulary acts as the drug benefit payor’s economic gate 
that keeps a $400 headache drug from being prescribed to 
customers of XYZ health plan; their Plan makes a 
privately-determined cost savings decision to not include a certain 
new headache drug in the Formulary. So, the electronic system of 
the payer automatically blocks the $400 option for the headache 
treatment, while that formulary allows $4 aspirin or $7 Tylenol, 
for example. Sitting at the CVS pharmacy waiting for that 
prescription to be filled, Ms. Jones has no idea of the hidden role of 
                                                                                                     
 17. 21 U.S.C. § 355 (2012). 
 18. 21 C.F.R. §§ 314.70, 314.80 (2018). 
 19. See 21st Century Cures Act § 3037 (amending 21 U.S.C. § 352(a)). 
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Pharmacy Benefit Managers. Recall the scene in the “Wizard of 
Oz” when the snake oil salesman from Kansas who plays the role 
of Oz tells Dorothy: “Pay no attention to that man behind the 
curtain!”20 And so decisions today are fast, and denials are less 
frequent if the prescriber cooperates. 
I realize that this new pharmaceutical sales cycle gets very 
complex very quickly, which is why so few members of Congress 
understood what they voted for in Section 3037 of the very complex 
recent drug legislation. The lobbyists for the drug developers 
designed this section to serve as a plausible 2016 alternative to the 
decades-old requirement for drug sponsors to be filing clinical 
study data with FDA for a “supplemental new drug application.”21 
They told Congress it was faster and cheaper to allow the 
“Formulary Fix” for these second and subsequent uses of an 
already approved drug. Consider a Formulary as an electronic list 
of privately reviewed drugs, the prescribing of which is 
commercially acceptable to a large health insurer like Humana, 
which will accept reimbursement of that drug for certain medical 
needs.  
The Formulary Fix means that the ability to electronically 
order the certain named drugs on the approved-use list will be 
available to doctors who work for the entities which take that 
insurer’s reimbursement, or whose bills are paid by the company 
under a contract. Doctors who use the drugs on that Formulary list 
have no problems; but doctors who want to prescribe a different 
drug that is not in the formulary have to spend non-compensated 
time to justify their preferred drug. I’ll use another model: doctors 
treating jaundice can use formulary listed drugs A or B; but if they 
want instead to use drug C, that is an exception to the Formulary, 
and they will have to spend their own time negotiating with the 
corporate staff for an exception which delivers that drug. Yes, 
hassling a distant phone contact to get another non-Formulary 
drug for a patient is not being reimbursed, so how often will doctors 
go “off Formulary” for a call-in support of a different drug for the 
needs of one patient? Press “00” if you don’t expect it to happen 
often.  
                                                                                                     
 20. L. FRANK BAUM, THE WONDERFUL WIZARD OF OZ (G.M. Co. 1900). 
 21. 21 C.F.R. §§ 314.70, 314.80. 
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So, from 2017 forward, if your company holds the new drug 
approval for an acne product, as our hypothetical case had 
addressed earlier, your preapproval team no longer need to visit 
beautiful White Oak, Maryland to argue with FDA review teams. 
Instead, one MBA will head to New York, Nashville, or Boston to 
a business office tower where economic choices and medical 
decisions are being made. Your technical sales person has power 
in 2017 and hereafter, as a result of Section 3037 of the 21st 
Century Cures Act, to inform the insurer that your drug cures 
hangnail and is cheap and easier to administer.  
This is now a normalized stream of product benefit 
information. No one needs to stop to ask FDA’s views on clinical 
efficacy. The net cost for those patients whose insurer will cover 
their drug is less. The sales reps now must try to convince that 
company to accept this drug into their “Formulary,” a list matching 
illnesses with drugs, a list that is optional and privately compiled, 
rather than a federally dictated program. Once you make that 
sales pitch successfully, the marketplace of all the patients and 
providers of the XYZ insurance group or a state Medicaid program 
will be opened to you; and doctors who belong to that health 
insurer’s group must begin or continue to use that selected drug 
for that “off label” medical indication.  
The actual prescriber doctor does not sit in, at the meeting 
when the drug maker pitches its drug’s additional use benefit to 
the insurer’s formulary committee. Hence, the FDA gatekeeper 
roles of the supplemental NDA are inoperative anachronisms,22 
and sales will be spurred. Congress ran right past the previous 
barrier to adding use information, and “liberated” the drug 
marketers for private communication to the few specialist medical 
committee members who are the buyers of their mass quantity of 
drugs, allowing drug makers to spin the “Formulary Fix”. 
V. Trump and Trends  
Old, tired veterans of those wars have been alarmed at the 
new Trump Administration leadership’s message regarding drug 
approvals. Past moments of reflection, like the 100th anniversary 
                                                                                                     
 22. 21 CFR §§ 314.70, 314.80. 
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symposium of the FDA in 2006, stimulated reflections on the 
balance between faster new product approvals, and more certain 
decisions in the field of drug safety. The earliest presentations to 
industry audiences by the new Commissioner, a longtime industry 
advisor and participant, sent a different message and a divergent 
tone to the FDA’s review teams. The words of Commissioner Scott 
Gottlieb could echo a pharmaceutical industry executive’s 
oft-repeated mantra—speed the data gathering and review, speed 
the approval, get the drug out today and check the “real world 
data” next year.23 It is too early in his leadership term to know 
where the acceptance of industry will lead, but there are balanced 
approaches that are at some risk of negative consequences in the 
Trump Administration’s pro-development rhetoric. 
VI. So What? 
Battling over the future use of off-label drug claims will be far 
less interesting to my hypothetical drug company executive after 
2017. She now can gain far more by pressing Humana or Aetna to 
place the additional drug benefit claim onto their private 
Formulary. If a doctor is in a hospital or practice group whose 
Formulary applies controls on what the affiliated physicians can 
prescribe, as so many practitioners are and will be, then the 
patient record indicates a certain diagnostic code and the patient 
gets a prescription for that drug for that non-labeled medical 
indication, and the sale is made without need for the old ways of 
chasing the off-label violators. The FDA cares less about hangnail; 
Jane Insured gets what Doctor Golfclub prescribes; and Golfclub is 
directed seamlessly by the drug Formulary, which allows her to 
prescribe this drug Alepsima for hangnail.  
So, in Shakespeare’s terms, I come to not just praise the Note 
by Hurley, but to bury his model of drug marketing. The 
                                                                                                     
 23. Scott Gottlieb, M.D., Comm’r of Food & Drugs, Remarks on Leveraging 
Quantitative Methods and Modeling to Modernize Generic Drug Development 
and Review (Oct. 2, 2017); Scott Gottlieb, M.D., Comm’r of Food and Drugs, 
Speech to the 2017 AdvaMed (MedTech) Conference (Sept. 26, 2017); Scott 
Gottlieb, M.D., Comm’r of Food and Drugs, Address to National Academy of 
Sciences, Advancing Public Health Opportunities with Real World Evidence 
(Sept. 19, 2017). 
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“Formulary Fix” of Section 3037 of the “21st Century Cures Act”24 
is where the marketers of drugs are headed in 2018 and beyond. 
The claims of additional benefit that had once languished in FDA’s 
in-box are beating a path to Humana’s or McKesson’s door.  
While a supplementary new drug application would be nice to 
have for the minority of doctors who are not impacted by a 
Formulary, the months and millions which such a voluminous 
drug application “supplement” demands25 are considerably less 
important to net sales goals than they once had been, way back in 
2015. The drug promotion effort of this brave new pharma world is 
not only centralized and simplified, it is also sanctioned by 
Congress as an alternate route to market success.  
How this all will play out remains to be seen, and “all the 
world’s a stage.” 
                                                                                                     
 24. See generally 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 
1033 (2016). 
 25. 21 C.F.R. §§ 314.70, 314.80 (2018). 
